Concurrent Session 6: Cytokines in OA

Concurrent Session

Date/Time: Friday, April 30, 2021 - 10:45 AM to 12:45 PM
Log in to Add to My Schedule


Is IL1 still the “OA Cytokine” 
Interleukin-1 has long been considered an important target in osteoarthritis (OA). However OA animal models have provided discrepant results on anti-IL-1 therapies, perhaps in part reflecting not only different animal models but prophylactic versus therapeutic experiments. Human clinical studies of IL-1 inhibition in OA have also generally been disappointing, though such studies have also had limitations, including issues with study entry characteristics and relatively short-term use of treatments. Recently a posthoc analysis of a large trial of the IL-1 inhibitor canakinumab, in which patients selected for cardiovascular disease and elevated inflammatory markers (but not OA), demonstrated a marked reduction in total joint replacements in all active drug arms. This recent data may warrant reconsideration of the role of interleukin-1 inhibition in OA.

Followed by abstract presentations.